Last reviewed · How we verify
I.V. palonosetron
Palonosetron is a selective 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract to prevent nausea and vomiting.
Palonosetron is a selective 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract to prevent nausea and vomiting. Used for Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV), Prevention of post-operative nausea and vomiting (PONV).
At a glance
| Generic name | I.V. palonosetron |
|---|---|
| Sponsor | Helsinn Healthcare SA |
| Drug class | 5-HT3 receptor antagonist |
| Target | 5-HT3 receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Palonosetron binds with high affinity and selectivity to 5-hydroxytryptamine type 3 (5-HT3) receptors, which are located on vagal afferents in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By antagonizing these receptors, it prevents the emetic signals triggered by chemotherapy, radiation, or post-operative conditions from reaching the vomiting center.
Approved indications
- Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
- Prevention of post-operative nausea and vomiting (PONV)
Common side effects
- Headache
- Constipation
- Diarrhea
- Dizziness
- Fatigue
Key clinical trials
- TEAS Combined With Triple Antiemetic Drugs to Prevent PONV in High-Risk Patients (NA)
- An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting (PHASE3)
- Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy (NA)
- An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting (PHASE3)
- Palonosetron for the Treatment of Nausea and Vomiting in Terminally Ill Patients (PHASE2)
- Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab (PHASE2)
- Aprepitant for Prevention of Acute and Delayed Nausea and Vomiting in Patients Receiving a High-emetogenic Dose of Cyclophosphamide for Peripheral Blood Stem Cells Harvesting (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- I.V. palonosetron CI brief — competitive landscape report
- I.V. palonosetron updates RSS · CI watch RSS
- Helsinn Healthcare SA portfolio CI